You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent or metastatic NPC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PD-1 Inhibitor, G-CSF Trial in Guangzhou (Camrelizumab, G-CSF)

Recruiting
  • PD-1 Inhibitor
  • G-CSF
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2022

Recurrent or Metastatic NPC Trial in Hong Kong (Axitinib, Avelumab)

Recruiting
  • Recurrent or Metastatic NPC
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Prince of Wales Hospital, The C
Jul 18, 2022

Nasopharyngeal Carcinoma Trial in Zhongshan (Anrotinib plus Tirelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anrotinib plus Tirelizumab
  • Zhongshan, Guangdong, China
    Zhongshan City People's Hospital
Jul 31, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in Guanzhou (HLX07, HLX10, )

Not yet recruiting
  • Nasopharyngeal Carcinoma by AJCC V8 Stage
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 23, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Nasopharyngeal Carcinoma, Leucogen, Chemo Trial in Guangzhou (5-fu, Lobaplatin, Placebo)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Radiation Oncology, Sun Yat-Sen University Cancer
Mar 10, 2023

Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Trial in Shanghai (Fluzoparib and Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Cancer
  • Fluzoparib and Camrelizumab
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Jun 4, 2022

Oral Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Carrimycin)

Active, not recruiting
  • Oral Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong
May 13, 2021

Nasopharyngeal Tumors Trial in Guangzhou (gemcitabine and cisplatin, 5-Fluorouracil and cisplatin)

Completed
  • Nasopharyngeal Neoplasms
  • gemcitabine and cisplatin
  • 5-Fluorouracil and cisplatin
  • Guangzhou, Guangdong, China
    Department of Medical Oncology,Cancer Center of Sun Yat-Sen Univ
Sep 27, 2021

Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma Trial in Worldwide (Nanatinostat,

Recruiting
  • Nasopharyngeal Carcinoma
  • +4 more
  • Lynwood, California
  • +20 more
Jul 27, 2022

Recurrent or Metastatic NPC Trial in China, Singapore, Taiwan (TORIPALIMAB INJECTION(JS001 ) combine with chemo, Placebos)

Active, not recruiting
Has Results
  • Recurrent or Metastatic NPC
  • TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
  • Placebos
  • Beijing, Beijing, China
  • +31 more
Apr 15, 2022

Advanced Nasopharyngeal Carcinoma Trial in Hangzhou (SBRT)

Recruiting
  • Advanced Nasopharyngeal Carcinoma
  • SBRT
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Dec 5, 2022

Nasopharyngeal Tumors Trial (The combination treatment of anlotinib, penpulimab and capecitabine.)

Not yet recruiting
  • Nasopharyngeal Neoplasms
  • The combination treatment of anlotinib, penpulimab and capecitabine.
  • (no location specified)
Apr 10, 2023

Cadonilimab in Recurrent or Metastatic Cervical Cancer

Not yet recruiting
  • Recurrent or Metastatic Cervical Cancer
  • (no location specified)
Nov 23, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1210)

Completed
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Apr 1, 2022

Nasopharyngeal Carcinoma Trial in Fuzhou (EBV-TCR-T (YT-E001) cells)

Unknown status
  • Nasopharyngeal Carcinoma
  • EBV-TCR-T (YT-E001) cells
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Aug 9, 2020

Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

Active, not recruiting
  • Recurrent Nasopharyngeal Carcinoma
  • +2 more
  • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
  • Guangzhou, Guangdong, China
    Yanqun Xiang
Sep 5, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1701, Gemcitabine, Cisplatin)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Hospital of Guangzhou Sun Yat-sen University
Dec 19, 2021

Cervical Cancer Trial (Nimotuzumab?Tislelizumab)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Sep 9, 2023

Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma Trial (Durvalumab,

Withdrawn
  • Epstein-Barr Virus Positive
  • +6 more
  • (no location specified)
Oct 22, 2020

Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer Trial (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Recurrent Vulvar Cancer
  • +3 more
  • (no location specified)
Jun 12, 2023

AK104 Combined With I-125 Brachytherapy for Recurrent or

Not yet recruiting
  • Cervical Cancer
  • Iodine-125 particle brachytherapy
  • AK104
  • (no location specified)
Sep 25, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023